The BiTE targets CD19 on cancerous cells and CD3 on the surface of T-cells. Credit: even_huang via Shutterstock. · Clinical Trials Arena · even_huang via Shutterstock. The above button links to ...
Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives. AZD0486 is a novel IgG ...
AZD0486 demonstrated encouraging safety and dose-dependent efficacy in heavily pretreated adolescent and adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), according to ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is currently conducting a ...
Survival outcomes of Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified: Results from Latin American and United States cohorts. This is an ASCO Meeting Abstract from ...
The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis. Additionally, the launch ...
At the recent American Society of Hematology (ASH) annual meeting, data from a phase I trial of AZD0486-- a novel CD19xCD3 bispecific T-cell engager -- showed high response rates and encouraging ...
SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results